These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 9751198)

  • 1. Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's patients.
    Terrisse L; Poirier J; Bertrand P; Merched A; Visvikis S; Siest G; Milne R; Rassart E
    J Neurochem; 1998 Oct; 71(4):1643-50. PubMed ID: 9751198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer's disease: no relation to apolipoprotein E expression or genotype.
    Thomas EA; Laws SM; Sutcliffe JG; Harper C; Dean B; McClean C; Masters C; Lautenschlager N; Gandy SE; Martins RN
    Biol Psychiatry; 2003 Jul; 54(2):136-41. PubMed ID: 12873803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of apolipoprotein D and apolipoprotein E expression in rat hippocampus after entorhinal cortex lesion.
    Terrisse L; Séguin D; Bertrand P; Poirier J; Milne R; Rassart E
    Brain Res Mol Brain Res; 1999 Jun; 70(1):26-35. PubMed ID: 10381540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hippocampal apolipoprotein D level depends on Braak stage and APOE genotype.
    Glöckner F; Ohm TG
    Neuroscience; 2003; 122(1):103-10. PubMed ID: 14596852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
    Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
    Oláh Z; Kálmán J; Tóth ME; Zvara Á; Sántha M; Ivitz E; Janka Z; Pákáski M
    J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein E levels in the cerebrospinal fluid of north Indian patients with Alzheimer's disease.
    Kandimalla RJ; Wani WY; Anand R; Kaushal A; Prabhakar S; Grover VK; Bharadwaj N; Jain K; Gill KD
    Am J Alzheimers Dis Other Demen; 2013 May; 28(3):258-62. PubMed ID: 23612909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-dependent decline in the apolipoprotein E level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer's disease.
    Fukuyama R; Mizuno T; Mori S; Yanagisawa K; Nakajima K; Fushiki S
    Eur Neurol; 2000; 43(3):161-9. PubMed ID: 10765057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein D is a component of compact but not diffuse amyloid-beta plaques in Alzheimer's disease temporal cortex.
    Desai PP; Ikonomovic MD; Abrahamson EE; Hamilton RL; Isanski BA; Hope CE; Klunk WE; DeKosky ST; Kamboh MI
    Neurobiol Dis; 2005 Nov; 20(2):574-82. PubMed ID: 15916898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein D: a potential biomarker for cerebral amyloid angiopathy.
    Kuiperij HB; Hondius DC; Kersten I; Versleijen AAM; Rozemuller AJM; Greenberg SM; Schreuder FHBM; Klijn CJM; Verbeek MM
    Neuropathol Appl Neurobiol; 2020 Aug; 46(5):431-440. PubMed ID: 31872472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein D.
    Rassart E; Bedirian A; Do Carmo S; Guinard O; Sirois J; Terrisse L; Milne R
    Biochim Biophys Acta; 2000 Oct; 1482(1-2):185-98. PubMed ID: 11058760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease.
    Zimetti F; Caffarra P; Ronda N; Favari E; Adorni MP; Zanotti I; Bernini F; Barocco F; Spallazzi M; Galimberti D; Ricci C; Ruscica M; Corsini A; Ferri N
    J Alzheimers Dis; 2017; 55(1):315-320. PubMed ID: 27662294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients.
    Gabriel AJ; Almeida MR; Ribeiro MH; Durães J; Tábuas-Pereira M; Pinheiro AC; Pascoal R; Santana I; Baldeiras I
    Neurosci Lett; 2017 Feb; 641():101-106. PubMed ID: 28108398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease.
    Johansson P; Almqvist EG; Bjerke M; Wallin A; Johansson JO; Andreasson U; Blennow K; Zetterberg H; Svensson J
    J Alzheimers Dis; 2017; 59(3):1017-1026. PubMed ID: 28697566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hippocampal alterations of apolipoprotein E and D mRNA levels in vivo and in vitro following kainate excitotoxicity.
    Montpied P; de Bock F; Lerner-Natoli M; Bockaert J; Rondouin G
    Epilepsy Res; 1999 Jun; 35(2):135-46. PubMed ID: 10372566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of apolipoprotein E (apoE) in cerebrospinal fluid.
    Hesse C; Larsson H; Fredman P; Minthon L; Andreasen N; Davidsson P; Blennow K
    Neurochem Res; 2000 Apr; 25(4):511-7. PubMed ID: 10823584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased CSF cortisol in AD is a function of APOE genotype.
    Peskind ER; Wilkinson CW; Petrie EC; Schellenberg GD; Raskind MA
    Neurology; 2001 Apr; 56(8):1094-8. PubMed ID: 11320185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent.
    Beffert U; Cohn JS; Petit-Turcotte C; Tremblay M; Aumont N; Ramassamy C; Davignon J; Poirier J
    Brain Res; 1999 Oct; 843(1-2):87-94. PubMed ID: 10528114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.